PloS one

pakistan journal of pharmaceutical sciences

BMC infectious diseases

Environmental monitoring and assessment

The Pan African medical journal

Gene

journal of hepatology

harm reduction journal

health and human rights

african journal of primary health care & family medicine

liver international : official journal of the international association for the study of the liver

clinical transplantation

journal of viral hepatitis

Journal of acquired immune deficiency syndromes (1999)

journal of the american board of family medicine : jabfm

Arquivos de gastroenterologia

journal of infection in developing countries

hepatology research : the official journal of the japan society of hepatology

World journal of virology

[1] The testing of people with any risk factor for Hepatitis C in community pharmacies is cost effective.

[2] Characterization of the hepatitis C virus epidemic in Pakistan.

[3] Strategies to manage hepatitis C virus infection disease burden - volume 3.

[4] The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.

[5] Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.

[6] Effect of phenological stages on nutritional assessment of ten plant species in Tehsil Takht-e-Nasrati, District Karak, Pakistan.

[7] Monitoring of Coliforms and chlorine residual in water distribution network of Rawalpindi, Pakistan.

[8] Moral Distress with Obstacles to Hepatitis C Treatment: A Council of Academic Family Medicine Educational Research Alliance (CERA) Study of Family Medicine Program Directors.

[9] New Insights into the Rational Use of HCV+ Organs Worldwide.

[10] Progress and Challenges in a Pioneering Hepatitis C Elimination Program in the Country of Georgia, 2015-2018.

[11] The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events.

[12] The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C.

[13] Post-treatment levels of α-fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C.

[14] Evaluation of biochemical, hematological, RIBA and PCR assays in predicting viremia in anti-HCV positive patients.

[15] demographic characteristics and intravenous drug use among hepatitis c patients in the kota setar district, kedah, malaysia

[16] cd8αα expression marks terminally differentiated human cd8+ t cells expanded in chronic viral infection

[17] survival benefits of interferon-based therapy in patients with recurrent hepatitis c after orthotopic liver transplantation

[18] hepatitis c viral load does not predict disease outcome: going beyond numbers a carga viral do vírus da hepatite c não prediz a evolução: indo além dos números

[19] treatment of autoimmune haemolytic anaemia with hepatitis c virus-a real challenge

[20] risk factors and seroprevalence of hepatitis b, c, and d virus in hemodialysis patients in istanbul

[21] neuroimaging findings in chronic hepatitis c virus infection: correlation with neurocognitive and neuropsychiatric manifestations

[22] plasma hydroxy-metronidazole/ metronidazole ratio in hepatitis c virus-induced liver disease

[23] viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis c cinética viral durante el primer mes de tratamiento en pacientes con hepatitis crónica c genotipo 1

[24] prevalence of risk factors for hepatitis c and associated factors: a population-based study in southern brazil

[25] treatment of chronic hepatitis c among injecting drug users: a 5-year follow-up

[26] factors associated with failure of clinical screening among blood donors who have altered serological results in the centro regional de hemoterapia de ribeirão preto

[27] the treatment outcome and impact on blood transfusion demand of peg-interferon/ribavirin in thalassemic patients with chronic hepatitis c

[28] hepatitis c among former athletes: association with the use of injectable stimulants in the past

[29] increased oral lichen planus in a chronic hepatitis patient associated with elevated transaminase levels before and after interferon/ribavirin therapy

[30] aplicação do modelo de crenças em saúde na prevenção dos acidentes com agulha application of the health belief model to the prevention of occupational needlestick injuries

[31] protective immunity against hepatitis c: many shades of grey

[32] los criterios de elegibilidad actuales del seguro popular para recibir tratamiento para el virus de la hepatitis c

[33] resultado do inquérito nacional sobre condutas no acompanhamento e no tratamento da recurrência da hepatite c em portadores de vírus c submetidos a transplante de fígado national survey about management and treatment options of hepatitis c recurrence after liver transplantation

[34] population changes of colon lumen microbiota in patients with chronic hepatitis c

[35] seroprevalence of acute hepatitis c virus infection among mortuary workers and ambulance drivers in plateau state, nigeria

[36] frecuencia de hepatitis b y c en adultos con hemopatías malignas frequency of hepatitis b and c in adults with malignant hemopathies

[37] il28b gene polymorphisms in mono- and hiv-coinfected chronic hepatitis c patients

[38] necrolytic acral erythema in seronegative hepatitis c

[39] clinical and epidemiological aspects of hepatitis b virus and hepatitis c virus in fortaleza-ceara

[40] association between phase angle, anthropometric measurements, and lipid profile in hcv-infected patients

[41] the role of single nucleotide polymorphisms of cytokine genes in viral infections

[42] potential of g-csf supplementation to counter the neutrophil effects of standard peg-ifnα plus ribavirin combination therapy for treating hcv-related cirrhosis

[43] cd161+cd4+ t cells are enriched in the liver during chronic hepatitis and associated with co-secretion of il-22 and interferon-gamma

[44] nk cell function and receptor diversity in the context of hcv infection

[45] Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report.

[46] INAPPROPRIATE USAGE OF INTRAVENOUS PROTON PUMP INHIBITORS AND ASSOCIATED FACTORS IN A HIGH COMPLEXITY HOSPITAL IN BRAZIL.

[47] Epidemiology and natural history of HCV infection - Nature Reviews Gastroenterology & Hepatology

[48] Direct-acting antiviral agents for HCV infection affecting people who inject drugs - Nature Reviews Gastroenterology & Hepatology

[49] Performance evaluation of NeuMoDx 96 system for hepatitis B and C viral load.

[50] Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

[51] Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population.

[52] How expensive may drugs be? The example of hepatitis C drugs

[53] Prediction and Staging of Hepatic Fibrosis in Children with Hepatitis C Virus: A Machine Learning Approach.

[54] Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

[55] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[56] Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

[57] Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

[58] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

[59] Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

[60] Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

[61] Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

[62] Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

[63] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

[64] Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

[65] Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

[66] Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

[67] Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

[68] Conceptual framework for outcomes research studies of hepatitis C: an analytical review

[69] Influence of host resistance on viral adaptation: hepatitis C virus as a case study

[70] Approaches to hepatitis C treatment and cure using NS5A inhibitors

[71] Current treatment of choice for chronic hepatitis C infection

[72] New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

[73] Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

[74] Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

[75] Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

[76] Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

[77] Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

[78] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[79] Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

[80] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[81] Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

[82] Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

[83] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

[84] Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

[85] Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

[86] Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

[87] Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

[88] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

[89] Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

[90] Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

[91] Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

[92] Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

[93] Conceptual framework for outcomes research studies of hepatitis C: an analytical review

[94] Influence of host resistance on viral adaptation: hepatitis C virus as a case study

[95] Approaches to hepatitis C treatment and cure using NS5A inhibitors

[96] Current treatment of choice for chronic hepatitis C infection

[97] New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

[98] Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

[99] Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

[100] Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

[101] Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series